Cite

    Simpson, K. et al. (2022). Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events. Expert review of pharmacoeconomics & outcomes research. pp. 671-681. [Online].